Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study

Hoo Rim Song1,2, Won-Myong Bahk2, Young Sup Woo3, Jong-Hyun Jeong2, Young-Joon Kwon1, Jeong Seok Seo3, Won Kim3, Moon-Do Kim5, Young-Chul Shin6, Sang-Yeol Lee7, Kyung Joon Min8

Department of Psychiatry, 1Soonchunhyang University Cheonan Hospital, Cheonan, 2College of Medicine, The Catholic University of Korea, Seoul, 3Konkuk University Chungju Hospital, Chungju, 4Inje University Seoul Paik Hospital, Seoul, 5Jeju National University Hospital, Jeju, 6Kangbuk Samsung Hospital, Seoul, 7Wonkwang University Hospital, Iksan, 8Chung-Ang University Hospital, Seoul, Korea

Objective: Mirtax is a generic mirtazapine widely used since 2003. We conducted an open-label, uncontrolled 6-week study to evaluate the efficacy and safety of Mirtax for major depressive disorder (MDD).

Methods: Ninety three MDD patients with the diagnosis of MDD and 17-item Hamilton Depression Rating Scale (HDRS) score ≥14 were recruited. The HDRS, Montgomery–Åsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions–Severity Scale (CGI–S) were administered at baseline, 1, 2, 4 and 6 weeks. Response (≥50% decrease in the HDRS or MADRS score), remission (absolute HDRS score ≤7 or MADRS score ≤10) and CGI–I score ≤2 were also calculated. Adverse event (AE) frequency and severity, weight, blood pressure, and pulse rate were checked to assess safety.

Results: The starting dosage was 11.5±6.4 mg/day, and the maintenance dosage was 23.1±9.4 mg/day. During 6 weeks, HDRS, MADRS and CGI–S scores decreased from 25.1±5.6 to 11.9±8.6 (mean change –13.1±8.3, p<0.001), from 30.2±6.3 to 13.7±8.5 (mean change –16.5±9.8, p<0.001), and from 5.0±0.8 to 2.5±1.3 (mean change –2.5±1.3, p<0.001), respectively. The percentages of responders, remitters by HDRS and patients with a CGI–I score ≤2 were 64.6%, 35.4% and 52.7%, respectively. Significant decreases in HDRS, MADRS and CGI–S scores were confirmed at week 1. The total rate of AEs was 32.3%; the most frequently reported AEs were sedation (4.3%) and constipation (4.3%). Weight was increased from 58.8±10.6 to 60.3±9.3 kg (mean change 0.7±1.7 kg, p=0.004).

Conclusion: This study, as the first clinical trial of generic mirtazapine, demonstrated the efficacy and tolerability of Mirtax for MDD using a single treatment design.

KEY WORDS: Mirtazapine; Generic drugs; Efficacy; Tolerability.

INTRODUCTION

Depression is a common and longstanding illness, which contributes to the major global burden of disease. In 2009, the World Health Organization states that approximately 350 million people suffered depression, and it is the second leading cause of disability worldwide.1) Antidepressants can be an effective form of treatment for major depressive disorder (MDD). Among them, mirtazapine is a widely used antidepressant due to its unique pharmacological profile and good psychiatric efficacy. It mainly blocks 5-hydroxytryptamine (5-HT2), 5-HT1 and α2-auto and heteroreceptors, subsequently enhancing noradrenergic and serotonergic transmission. It also acts as a potent histamine receptor antagonist, which causes a sedative effect.2) Mirtazapine showed good antidepressant efficacy equal to selective serotonin reuptake inhibitor (SSRI)3) or serotonin-norepinephrine reuptake inhibitor (SNRI),4) and advantages especially in the early course of treatment.5)

Since 1996, mirtazapine has been internationally available for the treatment of MDD, including in the United States. During this period, many generic forms of mirtazapine were released following bioequivalence tests. Mirtax (Sandoz Co.) is a widely used generic mirtazapine that was approved by the United States Food and Drug Administration in 2003. In fact, most generics are released following evidence that their pharmacokinetics are similar to those of the original drug,6) and few clinical trials...
have been conducted. Because of the similar pharmacokinetic profiles, we presume that the effects of generic mirtazapines are similar to those of branded mirtazapine. However, generic drug sometimes did not show the efficacy as same as branded drug. About paroxetine, there are potential differences in efficacy and safety between paroxetine mesylate and paroxetine hydrochloride. It also is unknown whether generic mirtazapine is effective or not due to a lack of evidence. Therefore, to evaluate the effects of generic mirtazapine, we conducted a phase 4 clinical trial of Mirtax film-coated tablets. This study simply focused on the Mirtax treatment itself without adopting any control group or switching design from branded medication. However, to our knowledge, this is the first clinical trial to evaluate the efficacy and tolerability of generic mirtazapine.

METHODS

Study Design
This was an open-label, uncontrolled, prospective 6-week study to evaluate efficacy and tolerability of Mirtax in MDD patients. It was conducted at 9 centres in Korea from June 2012 to December 2013. Recruitment was accomplished by recommendation from clinicians at the outpatient clinic without any advertisement process. Enrolment criteria were: (1) adult patients over 20 years of age who were diagnosed with MDD according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria, (2) a 17-item Hamilton Depression Rating Scale (HDRS) score of ≥ 14 at screening, (3) lack of sufficient treatment for the present episode or necessary medication changes due to tolerability problems. Sufficient pharmacological treatment was defined as using appropriate dosage of antidepressant for at least 6 weeks. Appropriate dosages were regarded as 20-40 mg/day of fluoxetine, 20-40 mg/day of paroxetine, 20-40 mg/day of citalopram, 10-20 mg/day of escitalopram, 50-200 mg/day of sertaline, 75-225 mg/day of venlafaxine and 150-300 mg/day of bupropion. Patients treated with mirtazapine at the point of screening that were also at risk for suicidality or other psychiatric diagnoses were excluded. The screening period was within 2 weeks before baseline measurement; however, when patients had no specific reason for disqualified, screening was permitted following baseline measurement on the same day. Previous antidepressants were stopped after screening. Exclusion criteria were pregnancy or lactation, a medical condition that could interfere with everyday life activities, and psychotic symptoms or previous diagnosis of bipolar disorder or any psychotic disorder. Current primary diagnosis other than MDD, lack of responses during current or a past episode of depression to two or more antidepressant at clinically appropriate doses for a minimum of 6 weeks, and severe suicidal risk were also under the exclusion criteria.

The visit schedule included: screening, baseline, and 1, 2, 4, and 6 weeks. During that period, dosages were started and maintained flexibly at the discretion of the investigator. Any other antidepressants, antipsychotics, mood stabilizers, psychostimulants and buspirone were prohibited; benzodiazepine (≤ 3 mg/day of lorazepam-equivalent dosage) and hypnotics were allowed.

The study was conducted according to the Declaration of Helsinki and Good Clinical Practice. Informed consent was obtained from all participants following an extensive explanation of the nature and procedures of the study. The study protocol was approved by the Institutional Review or Ethics Committee of each study site.

Efficacy and Tolerability Assessments
Efficacy was evaluated using the HDRS, Montgomery-Åsberg Depression Rating Scale (MADRS), the Clinical Global Impressions-Severity Scale (CGI-S) and the Clinical Global Impressions-Improvement Scale (CGI-I). The primary efficacy was measured as the mean HDRS change from baseline to week 6. Additional efficacy measures included the mean changes in MADRS, CGI-S scores, and response, remission, and CGI-I ≤ 2 rates at week 6. A response was defined as a ≥ 50% decrease in the HDRS or MADRS score, and remission was defined as an absolute HDRS score ≤ 7 or MADRS score ≤ 10.

Tolerability and safety were evaluated with the frequency and severity of AEs, and mean changes in weight, blood pressure, and pulse rate from baseline to week 6. AEs were filled up in the constructed response questionnaire in the Novartis Adverse Event Report Form.

Statistical Analyses
Efficacy and safety were analysed in an intent-to-treat (ITT) group, and the last-observation-carried-forward (LOCF) method was applied for endpoint analysis. All patients who received at least one dosage of the study medication were included in the safety analysis.

Data are presented as means-standard deviation for quantitative variables and frequencies (percentage) for categorical variables. Quantitative data were analysed by Student’s t-tests and categorical data were analysed by chi-squared tests. Repeated measures analysis of variance
(ANOVA) was used to determine the changes in group with adjusting for the time and repeated measures analysis of covariance (ANCOVA) with baseline score as covariate also used to check the different decreases between mild to moderate and severe subgroups. Response and remission rates of each subgroup were also compared. Analyses were performed using SAS software (ver. 9.2; SAS Institute Inc., Cary, NC, USA). Statistical significance was defined as $p < 0.05$.

RESULTS

Patients and Medications

After screening, a total of 93 patients (70 females, 75.3%) entered the study (Table 1). Most patients (61, 65.6%) were in their 40s. Seventy-two patients (77.4%) were free from antidepressant treatment at baseline, and 65 patients (69.9%) had a prevalence period of less than 1 year. Baseline HDRS, MADRS and CGI-S scores were 25.0±5.6, 30.3±6.3 and 5.0±0.8, respectively. Mean starting dosage at baseline was 11.5±6.4 mg/day and mean maintenance dosage at week 4 was 23.1±9.4 mg/day.

Fourteen patients (15.1%) cancelled their consents due to simple change of mind during the first week and were regarded as baseline dropouts. Other dropouts were due to loss to follow-up (17, 18.3%), adverse events (7, 7.5%), protocol violations (4, 4.3%), low compliance (1, 1.1%), and one quit at the discretion of the investigator (1.1%). At the end of the trial, 49 patients (52.7%) finished the study. ITT analyses included a initially total 93 patients.

Efficacy

At week 6, the HDRS and MADRS scores were decreased to 11.9±8.6 (mean change $-13.1±8.3$, $p < 0.001$; Fig. 1) and 13.73±10.40 (mean change $-16.5±9.8$, $p < 0.001$; Fig. 2). The percentages of responders were 64.6% (HDRS) and 60.8% (MADRS), and those of patients in remission were 35.4% (HDRS) and 43.0% (MADRS) (Table 2). CGI-S was decreased to 2.5±1.3 (mean change $-2.5±1.3$, $p < 0.001$) and there were 49 patients (52.7%) with a CGI-I score $\leq 2$. Significant decreases in HDRS, MADRS and CGI-S scores were confirmed at week 1. The response and remission rate also showed great increase during the first week (Table 2).
Table 2. Percentage of patients classified as responders and remitters by HDRS and MADRS score

| Time  | HDRS Response rate | HDRS Remission rate | MADRS Response rate | MADRS Remission rate |
|-------|-------------------|---------------------|---------------------|---------------------|
| Week 1 | 13.9              | 6.3                 | 11.4               | 6.3                 |
| Week 2 | 44.3              | 16.5                | 41.8               | 16.5                |
| Week 4 | 50.6              | 29.1                | 54.4               | 31.6                |
| Week 6 | 64.6              | 35.4                | 60.8               | 43.0                |

HDTRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale.

Fig. 3. Difference in decreases of Hamilton Depression Rating Scale (HDRS) score between mild to moderate-to-moderate patients and severe patients.

When participants were divided into a mild-to-moderate subgroup (baseline HDRS ≤24, n=48) and a severe subgroup (baseline HDRS >24, n=45), their decreases of HDRS scores from baseline were significantly different between two subgroups (p=0.006, Fig. 3). That is, the HDRS scores were more decreased in the severe subgroup than in the mild-to-moderate subgroup. It was much the same for the MADRS scores (p=0.012). However, final response rates at week 6 were not different as 68.2% (mild-to-moderate subgroup) and 60.0% (severe subgroup, p=0.125), while the remission rates were significantly different as 47.7% (mild-to-moderate subgroup) and 20.0% (severe subgroup, p<0.001).

Adverse Events (AEs) and Safety

There were a total of 45 AEs in 30 patients, and the total AE rate was 32.3%. The most frequently reported adverse events were sedation (4.3%) and constipation (4.3%), followed by dyspepsia (3.2%) and thirst (3.2%) (Table 3). Among them, about two-thirds (30 cases) were mild in severity, and nine cases of adverse events in seven patients (7.3%) were related to the drug. Three cases of severe adverse events occurred in three patients (3.2%), including suicide, unintentional drug intoxication and acute tonsillitis, of which causalities with drug were low.

Twenty-nine patients received no AE treatment, and 23 patients remained in the trial, while 7 patients were withdrawn due to AEs. The AEs related with dropout were sedation (2), headache (2), thirst (1), dyspepsia (1) and suicide (1 patient). At the end of the trial, the AEs of 17 patients had improved, while 6 patients were still experiencing them.

Weight increased from 58.8±10.6 to 60.3±9.3 kg (mean change 0.7±1.7 kg, p=0.004) over 6 weeks. Systolic blood pressure did not change (from 119.5±5 to 118.8±12.0 mmHg, mean change -1.27±7.7 mmHg, p=0.222), but diastolic blood pressure was decreased from 77.1±9.4 to 75.9±8.9, mean change -2.4±8.1 mmHg, p=0.031). Pulse rate did not change (from 74.8±9.3 to 73.9±5.9 beats/min, mean change 0.5±6.4 beats/min, p=0.584). These findings were not clinically significant.

DISCUSSION

Although this study employed an open-label and non-comparative design, the results demonstrated the efficacy and tolerability of Mirtax for the treatment of MDD. Significant decreases in the HDRS, MADRS, and CGI-S scores over 6 weeks were confirmed. Rates of CGI-I score ≤2, responders and remitters at week 6 also further support the efficacy of Mirtax. Decreases of HDRS scores
During 6 weeks were found out more in severe subgroup, while the remission rate at 6 week was above two times more in mild-to-moderate patients group. The incidence of AEs was very low, and most AEs were tolerable and not severe. Drug causality was low, including the severe AEs.

How does it compare with branded mirtazapine? The results from between-groups design are hard to compare with single treatment of this study uniformly. Nevertheless, studies including ours and previous ones revealed generally similar character in efficacy at week 6. Wheatley et al.\textsuperscript{13} reported a 63.3% response rate and a 23.3% remission rate in a comparison study with fluoxetine. Benkert et al.\textsuperscript{14} reported a 58.3% response rate and a 40.9% remission rate in a comparison study with paroxetine. Asian people also showed similar efficacy in a comparison study with fluoxetine (58% response rate and 35% remission rate).\textsuperscript{15} In two meta-analyses, the pooled response rate for mirtazapine was 67.1%,\textsuperscript{16} which is in agreement with our findings (64.6%), but the remission rate for mirtazapine was 43.4%,\textsuperscript{17} which is somewhat higher than that reported here (35.4%, standard: HDRS score).

The most distinguished result about branded mirtazapine might have a faster onset of action. Many studies of branded mirtazapine showed efficacy prior to week 2 as compared with SSRIs, which was confirmed by a meta-analysis.\textsuperscript{18} Another meta-analysis indicated 13% response rate and 3.4% remission rate for mirtazapine in week 1.\textsuperscript{19} These findings coincided relatively well with our study which demonstrated significant improvements in both HDRS and MADRS, and 13.9% of response rate and 6.3% of remission rate at week 1. In addition, response rate and remission rate markedly rose to 44.3% and 16.5%, respectively, at week 2. Considering above findings, Mirtax may have a earlier efficacy similar to branded mirtazapine potentially.

In this study, one characteristic feature was revealed. The degree of decreasing HDRS and MADRS scores was more decrease in severe patients, while the remission rate of a mild-to-moderate subgroup (47.7%) was above two times more than that of a severe subgroup (20.0%). It suggested that mild-to-moderate subgroup seems to have a better therapeutic effect from Mirtax than severe subgroup, even though decreases of HDRS scores from baseline were more in severe subgroup.

About tolerability and safety, only 30 patients (32.3%) reported spontaneous AEs, which is about half of previous reports (68.1%\textsuperscript{14} and 66.4%\textsuperscript{20}). There was a 47.3% drop-out rate, which was higher than previous studies (40%).\textsuperscript{21,22} We collected AE reports from 84.9% of participants, with the exception of 14 patients who withdrew their consent by simple change of mind before the first week. Considering these points, this study demonstrated a very low incidence of AEs.

Among AEs, sedation was the most frequent, but its incidence (4.3%) was considerably lower than that of the branded drug, which has a sedative rate of up to 54%.\textsuperscript{23} Also dizziness which had been reported frequently in previous studies (19.7%)\textsuperscript{15} was not reported. These differences might be caused by the relatively low dosage used in this study. This study used a flexible dosage setting based on investigator judgment. As a result, the starting dosage was only 11.5±6.4 mg/day, and the maintenance dosage was 23.1±9.4 mg/day, which were relatively low compared with previous studies. The low incidence of AEs may support this notion.

In general, a higher starting dosage appears to increase sedation, although it decreases over time after repeat dosing.\textsuperscript{24} A higher dosage might have a less marked sedative effect when antihistamine activity is offset after increased noradrenergic transmission.\textsuperscript{25} The low incidence of sedation and other AEs might be due to the low starting and maintenance dosages. These results may be representative of real-world practice because many clinicians carefully prescribe mirtazapine at less than 15 mg/day from the beginning.

Finally, we confirmed that generic mirtazapine also causes weight gain; however, the degree of weight gain was not clinically significant. Weight gain of 0.7±1.7 kg during 6 weeks might occur naturally and regarded safe in the general clinical situation. Considering that two-thirds of AEs were mild and only 7.5% of AEs were related with drug. Mirtax was found to be well tolerated in real clinical situation.

Our study had a number of limitations including single treatment design and small number of participants. The process also was not as strict as phase 3 clinical trial. There was no formal inter-rater reliability assessment before the study. The average in demographic data was influenced by skewed data and hard to evaluate age and sex effects due to small sample size.

However, this study, as the first clinical trial of generic mirtazapine, demonstrated its efficacy and tolerability over 6 weeks. Additionally, it suggested that Mirtax had fast onset of action similar to branded mirtazapine, and the possibility of differences in side effect profiles.

Even though our initial study might not provide high level of evidence, it showed the importance of investigat-
ing the generic antidepressants. To address variability between branded and generic drugs, studies into switches from the branded to the generic drug would be more suitable. Further investigation and clinical experience are required to gather those evidences.

**Acknowledgments**

This study was supported by Sandoz. All data were collected and analyzed by DreamCIS, the CRO (Contract Research Organization) company.

**REFERENCES**

1. Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009;18:23-33.
2. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 2005;6:631-641.
3. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60 Suppl 17:18-22; discussion 46-48.
4. Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006;26:75-78.
5. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011;12:1623-1632.
6. Borghieni G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-1592.
7. Margolese HC, Wolf Y, Desmarais JE, Beaumier L. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol 2010;25:180-182.
8. Pae CU, Misra A, Ham BJ, Han C, Parkar AA, Masand PS. Paroxetine mesylate: comparable to paroxetine hydrochloride? Expert Opin Pharmacother 2010;11:185-193.
9. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-747.
10. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry 2008;192:52-58.
11. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4:28-37.
12. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855.
13. Wheatley DP, van Moftra M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998;59:306-312.
14. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663.
15. Hong CJ, Hu WH, Chen CC, Hsiang CC, Tsai SJ, Ruwe FJ. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003;64:921-926.
16. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008;22:843-848.
17. Thase ME, Nierenberg AA, Vrijlandt P, van Oers HJ, Schutte AJ, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010;25:189-198.
18. Watanabe N, Morimi IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressant agents for depression. Cochrane Database Syst Rev 2011; (12):CD006528.
19. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62:358-361.
20. Leinonen E, Karstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999;14:329-337.
21. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171.
22. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4:145-150.
23. Dewan MJ, Anand VS. Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis 1999;187:96-101.
24. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997;17:251-264.
25. Iwamoto K, Kawano N, Sasaki K, Kohmura K, Yamamoto M, Ebe K, et al. Effects of low-dose mirtazapine on driving performance in healthy volunteers. Hum Psychopharmacol 2013;28:523-528.